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Objective: The purpose of this study was to explore the accuracy of elevated liver function values, age,
gender, pancreatitis and cholecystitis as predictors of common bile duct stones (CBDS).
Methods: All patients operated on for gallstone disease over a period of 3 years in a Swedish county of
302 564 citizens were registered prospectively. Intraoperative cholangiography (IOC) was used to detect
CBDS.
Results: A total of 1171 patients were registered; 95% of these patients underwent IOC. Common bile
duct stones were found in 42% of patients with elevated liver function values, 20% of patients with a
history of pancreatitis and 9% of patients with cholecystitis. The presence of CBDS was significantly
predicted by elevated liver function values, but not by age, gender, history of acute pancreatitis or
cholecystitis. A total of 93% of patients with normal liver function tests had a normal IOC. The best
agreement between elevated liver function values and CBDS was seen in patients undergoing elective
surgery without a history of acute pancreatitis or cholecystitis.
Conclusions: Although alkaline phosphatase (ALP) and bilirubin levels represented the most reliable
predictors of CBDS, false positive and false negative values were common, especially in patients with a
history of cholecystitis or pancreatitis, which indicates that other mechanisms were responsible for
elevated liver function values in these patients.
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Introduction
Laparoscopic cholecystectomy can usually be performed with
limited resources. The presence of common bile duct stones
(CBDS), however, makes the procedure much more complicated
and time-consuming. Preoperative awareness of CBDS enables
better planning and facilitates the allocation of the necessary
resources. In areas where more complicated procedures are cen-
tralized to units at which the optimal competence and equipment
are available, it may be possible to avoid the need to perform
surgery for CBDS at units that are not prepared for this procedure
if the presence or absence of CBDS is known in advance.
A number of imaging techniques have been suggested as
methods to predict the presence of CBDS preoperatively, includ-
ing magnetic resonance cholangiopancreatography (MRCP) and
endoscopic retrograde cholangiopancreatography (ERCP), as well
as nomograms based on various preoperative data.1–3 However,
these methods are either invasive, implying a certain incidence of
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morbidity or even mortality, as in ERCP, expensive, as in MRCP, or
too complicated to gain acceptance in clinical practice, as in the
case of nomograms. By contrast, biochemical markers, such as
serum alkaline phosphatase (ALP) and bilirubin levels, are
cheaply and easily sampled and thus commonly used clinically as
predictors of CBDS. Despite the widespread use of these markers,
their predictive value has not been fully assessed. Previous studies
have often been based on selected patient samples or data
assembled retrospectively.2,4–6 No prospective, non-selected,
population-based studies on the ability of ALP and bilirubin to
predict CBDS have been performed. Most studies have focused on
patient groups with a high risk for CBDS (i.e. suspected CBDS
based on ultrasound [US] findings),5,7,8 a history of previous acute
biliary pancreatitis,5,8,9 jaundice,5,8 cholangitis5,8 or elevated liver
function tests.5,7,8 The characteristics of such patient groups may
affect the prevalence of CBDS and thereby also the negative and
positive predictive values (NPVs and PPVs) of the predictor. As
CBDS are encountered in only approximately 10% of an unse-
lected population undergoing cholecystectomy, a very large
number of patients is required to achieve a power sufficient to
assess the ability of different markers to predict CBDS. Very few
previous studies have included more than 100 patients.1–4 This has
resulted in a wide range (17–92%) of PPVs regarding the ability of
ALP and bilirubin levels to predict CBDS.1,5,8
If ALP and bilirubin levels are used as predictors, test results
must be obtained a few weeks before surgery so that the cholecys-
tectomy patient can be referred to the optimal unit in order to
ensure the presence of appropriate equipment and to plan the time
required for the procedure. However, CBDS may be passed spon-
taneously before surgery. Furthermore, some patients without
CBDS at the time of blood sampling may develop CBDS as a result
of stone migration from the gallbladder. The timing of sampling
thus involves balancing the time required for planning against the
risk for the occurrence of such events in the interval between the
decision to perform surgery and the time of surgery. Most previous
studies have been based on bilirubin and ALP sampled 1 or a few
days before surgery. The predictive ability of ALP and bilirubin
sampled at a time-point weeks before surgery has not been studied.
Therefore, this study aimed to explore the ability of bilirubin
and ALP sampled 1–4 weeks prior to surgery to predict CBDS in
a prospective, population-based setting, using intraoperative cho-
langiography (IOC) findings as a reference, and to analyse pos-
sible sources of false positive and false negative values. It also
aimed to explore the use of previous history of acute biliary pan-
creatitis or cholecystitis, age and gender as predictive factors for
CBDS and to study the effectiveness of using the preoperative
prediction of CBDS as a basis for referring patients with CBDS to
the unit most appropriate for their management.
Materials and methods
Study design and patients
The study was designed as a prospective, population-based study
performed in the county of Uppsala in Sweden. In December
2004, the population of this county numbered 302 564.10 All
patients who underwent cholecystectomy in Uppsala county from
1 January 2003 to 31 December 2005 were registered prospectively
according to a standardized protocol. All variables related to indi-
cations for surgery, history of acute cholecystitis or gallstone pan-
creatitis, surgical intervention, IOC results, serum bilirubin and
ALP levels, American Society of Anesthesiologists (ASA) physical
status classification score and age were recorded by the surgeon
undertaking the operation. Data related to the postoperative
course, including additional investigations such as the results of
possible postoperative cholangiography, were recorded by the
surgeon responsible for discharging the patient.
Setting
All of the three hospitals in the county that used the same
computer-based medical records participated in the study. These
included one university hospital (Uppsala University Hospital),
one short-stay clinic (Samariterhemmet) and one municipal hos-
pital (Enköping Hospital). When a procedure was anticipated to
be fairly complicated, as in cases of acute cholecystitis or suspected
CBDS, the patient was generally referred to the university clinic,
whereas procedures that were presumed to be uncomplicated were
conducted at the short-stay clinic. Procedures of intermediate
degrees of complicatedness were managed at the municipal hos-
pital. Preoperative planning aimed to avoid the performance of
surgery in patients with CBDS at the short-stay clinic because this
clinic provided health care during weekdays only and lacked an
intensive care unit.11 The short-stay clinic performed elective pro-
cedures only. Emergency procedures were usually performed only
at the university hospital because this was the only hospital with a
24-h surgical emergency unit. Patients with acute ongoing chole-
cystitis of less than 3–5 days’ duration were in general operated as
soon as possible. However, if a patient showed symptoms of
ongoing acute cholecystitis for more than 3–5 days, the surgery
was generally postponed for 2–3 months until the inflammatory
process had settled. The cholecystectomy was then performed at
the municipal or the university hospital.
Common bile duct stones found during laparoscopic cholecys-
tectomy were generally extracted during the primary operation.
Randomized trials have shown this to be more cost-effective and
to be associated with shorter hospital stays compared with extrac-
tion by postoperative endoscopic retrograde cholangiography.12–14
To ensure complete coverage, data collected were cross-checked
against data in the electronic patient administrative system
common to the three hospitals. This database contains data nec-
essary for planning and financing health care. All operations are
registered in this database. If any diagnosis or intervention code
raising suspicion of gallstone-related events was registered in the
electronic patient administrative system, that patient’s computer-
based medical records were reviewed. A second review of the
records of all patients for whom a pathological finding at cholan-
giography was recorded in the register was also carried out. In the
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present study, patients who underwent cholecystectomy for sus-
pected malignancy or as part of surgery carried out for other
indications were excluded.
Intraoperative cholangiography
In accordance with local guidelines in Uppsala county, IOC is
performed routinely in all patients undergoing cholecystectomy.11
The result of this IOC was used to test the predictive value of ALP
and bilirubin levels. If IOC was not performed as a result of
technical problems, the reasons for this were documented. An IOC
technique similar to that described by MacFadyen15 was used. This
method, which has been described in detail previously,16 resulted
in a dynamic real-time intraoperative fluoroscopic cholangiogram
obtained with a mobile C-arm X-ray apparatus (Ziehm Exposcop
CB7-D; Ziehm Imaging GmbH, Nuremburg, Germany), using
10–40 ml Johexol (Omnipaque®; GE Healthcare, Little Chalfont,
UK) (200 mg/ml) as contrast medium and 1 mg glucagon (Glu-
cagon®; Novo Nordisk A/S, Bagsvaerd, Denmark) (1 mg/ml) i.v.
to release any papillary spasm or, in patients with diabetes melli-
tus, 1–2 ml (20 mg/ml) i.v. butylscopolamine (Buscopan®;
Boehringer Ingelheim, Ingelheim am Rhein, Germany).
The dynamic IOC was interpreted by the surgeon and a radi-
ologist simultaneously using a two-way communication system.
The reliability of IOC as a method of diagnosing CBDS (i.e. the
number of false positive and false negative findings on IOC) was
assessed previously in the same cohort and presented in an earlier
paper.16 The sensitivity and specificity of IOC were found to be
97% and 99%, respectively. The presence of CBDS was verified by
common bile duct (CBD) exploration or ERCP in 95% of patients
in whom IOC indicated CBDS. Only 0.4% of the patients with
normal cholangiography were subsequently found to harbour
CBDS over a 38-month follow-up.16
Statistical methods
Positive and negative odds ratios (ORs), sensitivity, specificity,
PPVs, NPVs and accuracy were calculated for each predictor using
IOC as the reference. Overall agreement (i.e. accuracy) was
defined as the percentage of all patients in whom the predictor
tested predicted correctly. Multivariate logistic regression analysis
was performed in order to calculate the risk for CBDS associated
with each respective predictive factor. The accuracy of risk factors
that were found to be significantly associated with the presence of
CBDS was analysed separately. All statistical analyses were per-
formed using spss Version 16.0 for Windows (SSPS, Inc., Chicago,
IL, USA). A P-value of <0.05 was considered to indicate statistical
significance.
Values are given in numbers, percentages of all patients
(n = 1171) or, in cases for which the predictive ability of a predic-
tor was compared with findings on IOC, as the percentage of
patients who underwent successful IOC (n = 1117). Continuous
data are presented as medians and interquartile ranges.
Biochemical parameters
Serum ALP and bilirubin were measured within 4 weeks preop-
eratively using standard analysis methods. Elevated ALP was
defined as ALP > 5 mkat/l (normal range: 0.8–4.6 mkat/l). Elevated
bilirubin was defined as total bilirubin > 50 mmol/l (normal
range: 4–21 mmol/l). The cut-off levels for bilirubin were set rela-
tively high in order to avoid too many false positive findings.7,8
The diameter of the CBD is not reported routinely on abdomi-
nal US in Sweden and thus was not documented in our protocol.
Definitions
Acute cholecystitis was defined by the demonstration of clinical
symptoms typical of cholecystitis, such as right upper abdominal
pain or tenderness, fever, elevated C-reactive protein (CRP) and
stones present in a thickened, oedematous gallbladder on abdomi-
nal US or computed tomography (CT).
Acute pancreatitis was defined by the demonstration of elevated
serum amylase of more than four times the normal value (normal
range: 0.15–1.10 mkat/l), the presence of typical signs of pancre-
atitis on abdominal US or CT and typical clinical signs of pancre-
atitis, such as abdominal pain or tenderness, nausea or vomiting,
in the absence of any history or radiological signs of chronic
pancreatitis.
Biliary pancreatitis was represented by acute pancreatitis and
the presence of gallstones on CT or abdominal US in the absence
of any history, laboratory or radiological findings indicating
another aetiology of pancreatitis.
Results
The study included 1171 patients. The process by which the
cohort was assembled and the number of patients excluded are
presented in Fig. 1. No protocols were discarded in the study.
Baseline data for the population studied and for the different
hospitals participating in the study, including indications for
surgery, type of cholecystectomy, IOC findings and type of CBD
exploration, are presented in Table 1.
Prediction of common bile duct stones
In univariate and multivariate logistic analyses of factors predicting
the presence of CBDS, elevated liver function values were found to
be significantly and independently associated with the presence of
CBDS, whereas age, gender and history of acute biliary pancreatitis
or acute cholecystitis were not (Table 2). Agreements between
elevated liver function values, history of acute biliary pancreatitis,
cholecystitis and the presence of CBDS are presented in Table 3.
Subgroup analysis
Levels of ALP and bilirubin may be elevated by mechanisms that
are not related to CBDS. We therefore calculated the ORs and
agreements between elevated bilirubin and/or ALP and the pres-
ence of CBDS separately for the different hospitals, for different
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ASA classes and according to whether the patient was operated
electively or for acute disease. These data are presented in Table 4.
The best agreement between elevated liver function values and
presence of CBDS was seen in patients without acute pancreatitis
or cholecystitis and operated electively at the municipal hospital
or short-stay clinic. These groups also presented the highest ORs
(i.e. the relationship between patients with CBDS and elevated
liver function values compared with patients without CBDS and
with elevated liver function values was most distinct in these
groups).
Discussion
The prevalence of CBDS was found to be only 42% in patients
with elevated bilirubin or ALP levels. Although the risk for CBDS
in patients with normal ALP and bilirubin levels was only 6%, the
group was very large and thus almost half (48%) of the patients
with CBDS had normal ALP and bilirubin values. Thus, using
findings of normal ALP and bilirubin as indicators of the absence
of CBDS would imply that half of CBDS patients would remain
undetected.
Total number of cholecystectomies performed in the county
January 2003 to December 2005  
(according to hospital administrative database) 
n = 1343 
Cholecystectomy as a part of other procedures
n = 172 
Population of  Uppsala  county 2004
n = 302 8851 
University hospital 
n = 340 
Municipal hospital 
n = 417
Short-stay clinic 
n = 414 
Prospective registration of 
cholecystectomy for primary gallstone disease  
n = 1171 
Intraoperative cholangiography performed  n = 1117 
Intraoperative cholangiography not performed
n = 54 
Operated in other counties
n = 48 
Patients referred from other counties
n = 175 
Common bile duct stones 
n = 126 
Predictor
66
Pancreatitis 
Cholecystitis 
No common bile duct stones 
n = 991 
Predictor
 Liver test
Pancreatitis
Cholecystitis 
Predictor 
 Liver test   
Pancreatitis   
Cholecystitis  
↑
↑   Liver test ↑
% (Sensitivity) 
52%
21%
22%
n
26
28
% 
9% 
10%
30%
n
93
104
295
+ OR 
5.70
2.10
0.74
Figure 1 Flow chart describing the process of assembling the cohort under study
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There are several mechanisms that may explain the limited
value of ALP and bilirubin levels as predictors of CBDS. Figure 2
summarizes some of them. Common bile duct stones that are only
partially obstructive may not cause elevated bilirubin levels and
may generate false negative values. Stones may enter or pass from
the CBD spontaneously in the interval between blood sampling
and surgery, thereby generating both false positive and false nega-
tive values. Microlithiasis and sludge in the CBD may increase the
viscosity of the bile, causing levels of both ALP and bilirubin to
rise, but may pass undetected on IOC because they are flushed out
to the duodenum by the contrast medium, thus allowing a normal
IOC.17,18 Sphincter of Oddi dysfunction caused by stenosis or
spasticity of the sphincter of Oddi may result in elevated liver
function values and biliary pain in the absence of CBDS,19–22 and
conjugation defects, such as Gilbert’s syndrome, a common cause
of unconjugated hyperbilirubinaemia found in 5% of a healthy
population, may cause false positive values.23,24
The association between elevated liver function values and
findings of CBDS on IOC was weaker in patients with a history of
acute pancreatitis compared with patients without a history of
pancreatitis (Table 4). A suggested explanation for this difference
may be that the CBD is obstructed by the inflammatory process of
Table 1 Clinical data for the populations studied by whole group and by different hospital populations
Clinical data for the population studied
All University hospital Municipal hospital Short-stay clinic
Patient data
Patients, n (%) 1171 340 (29) 417 (36) 414 (35)
Female, n (%) 776 (66) 190 (60) 296 (71) 290 (70)
Male, n (%) 395 (34) 150 (44) 121 (29) 124 (30)
Age, years, median (IQR) 48 (36–59) 51 (36–63) 50 (36–61) 44 (35–56)
BMI, kg/m2, median (IQR) 26 (24–30) 27 (24–31) 26 (24–30) 26 (23–29)
Elevated ALP or bilirubin, n (%) 164 (14) 92 (27) 64 (15) 8 (2)
Pathological IOC, n (%) 152 (13) 94 (29) 72 (18) 49 (13)
CBDS, n (%) 134 (11) 70 (21) 44 (11) 20 (5)
Operation time, min, median (IQR) 105 (80–135) 120 (90–150) 110 (85–140) 85 (70–110)
Successful IOC, n (%) 1117 (95) 325 (96) 400 (96) 392 (95)
Mortality, n (%) 4 (0.3) 4 (1) 0 0
Type of surgery, n (%)
Elective procedure 986 (84) 210 (62) 363 (87) 412 (99)
Acute procedure 186 (16) 130 (38) 54 (13) 2 (0.5)
Indications for surgery, n (%)
Gallstone-related prandial pain 695 (60) 121 (36) 277 (66) 297 (72)
Pancreatitis 125 (11) 76 (22) 37 (9) 12 (3)
Ongoing cholecystitis 99 (8) 73 (22) 23 (6) 3 (0.7)
Previous cholecystitis 219 (19) 46 (14) 71 (17) 102 (25)
Ongoing and previous pancreatitis 8 (0.7) 5 (2) 3 (0.7) 0
Cholecystitis with imminent threat of perforation 25 (2) 19 (6) 6 (1) 0
Type of cholecystectomy, n (%)
Laparoscopic 922 (79) 169 (50) 361 (87) 392 (95)
Conventional 138 (12) 110 (32) 24 (6) 4 (1)
Conversion from laparoscopic to conventional 111 (10) 61 (18) 32 (8) 18 (4)
CBD exploration, n (%)a
Open bile duct exploration 77 (59) 56 (86) 16 5
Laparoscopic transcystic exploration 24 (18) 9 (14) 0 15
Laparoscopic bile duct exploration 28 (21) 0 28 0
Open transcystic exploration 1 (0.8) 0 0 1
All, n 130 65 44 21
aFigures in brackets represent the percentage of the total number of CBD explorations performed at the actual hospital
IQR, interquartile range; BMI, body mass index; ALP, alkaline phosphatase; IOC, intraoperative cholangiography; CBD, common bile duct
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Table 2 Multivariate logistic analysis of risk factors predicting pathologic cholangiography
Factor Univariate model Final multivariate model
OR 95% CI OR 95% CI
Age
<median (48 years) 1 Reference 1 Reference
median (48 years) 1.48 1.03–2.13 1.49 1.002–2.22
Gender
Female 1 Reference
Male 1.29 0.88–1.87
Biochemical markers
Bilirubin < 50 mmol/l and ALP < 5 mkat/l 1 Reference 1 Reference
Bilirubin > 50 mmol/l and ALP > 5 mkat/l 11.27 7.54–16.86 11.29 7.54–16.92
History of cholecystitis
No cholecystitis 1 Reference
Previous or ongoing cholecystitis 0.70 0.46–1.08
History of pancreatitis
No pancreatitis 1 Reference
Pancreatitis 2.13 1.34–3.41
Stepwise selection method with entry testing based on the significance of the score statistic, and removal testing based on the probability of a
likelihood ratio statistic based on maximum partial likelihood estimates
OR, odds ratio; 95% CI, 95% confidence interval; ALP, alkaline phosphatase
Table 3 Agreement between elevated ALP or bilirubin levels, pancreatitis, cholecystitis and findings of common bile duct stones on
intraoperative cholangiography
Predictor Total No CBDS CBDS PPV/NPV
ALP and bilirubin
Normal ALP and bilirubin 958 898 60 94% (NPV)
Elevated ALP and bilirubin 159 93 66 42% (PPV)
Specificity 91%
Sensitivity 52%
Total agreement 86%
Pancreatitis
No pancreatitis 987 887 100 90% (NPV)
Pancreatitis 130 104 26 20% (PPV)
Specificity 90%
Sensitivity 21%
Total agreement 82%
Cholecystitis
No cholecystitis 794 696 98 88% (NPV)
Cholecystitis 323 295 28 9% (PPV)
Specificity 70%
Sensitivity 22%
Total agreement 65%
Total, n 1117 991 126
PPV, positive predictive value; NPV, negative predictive value; ALP, alkaline phosphatase; CBDS, common bile duct stones
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Table 4 Correlation between elevated liver function tests and common bile duct stones in different subgroups of patients
IOC CBDS Elevated liver test PPV, % NPV, % Sens., % Spec., % Agr., % +OR -OR
Hospital
University clinic 325 62 90 44 91 64 81 78 3.39 0.44
Municipal clinic 400 44 61 38 94 52 89 85 4.89 0.53
Short-stay clinic 392 20 8 38 96 15 99 94 11.53 0.86
Operation
Emergency 172 44 72 49 91 80 71 73 2.75 0.29
Elective 945 82 87 36 94 38 94 89 5.81 0.66
ASA score
1–2 1032 109 144 40 94 52 91 87 5.56 0.53
3–5 82 15 14 57 90 53 91 84 5.92 0.51
Pancreatitis
Pancreatitis 130 26 42 31 85 50 72 68 1.79 0.69
No pancreatitis 987 100 117 45 95 53 93 89 7.36 0.51
Cholecystitis
Acute cholecystitis 130 19 35 37 94 68 80 78 3.45 0.39
No cholecystitis 794 98 116 44 93 52 91 86 5.59 0.53
All 1117 126 159 42 94 52 91 86 5.57 0.52
The table displays how well elevated bilirubin or ALP predicted CBDS in different subgroups of patients. Values are calculated from the number of
patients with successful intraoperative cholangiograms in each group. A high positive odds ratio (+OR) and agreement (Agr.) signify the high predictive
ability of a test. Thus, elevated liver function values predicted CBDS best among electively operated patients without a history of biliary pancreatitis
or cholecystitis operated at the short-stay clinic, indicating that other mechanisms may have been responsible for elevating liver function values in
acutely operated patients with a history of biliary pancreatitis or acute cholecystitis
IOC, intraoperative cholangiography; CBDS, common bile duct stones; PPV, positive predictive value; NPV, negative predictive value; Sens.,
sensitivity; Spec., specificity; Agr., agreement; +OR, positive odds ratio; -OR, negative odds ratio; ASA, American Society of Anesthesiologists; ALP,
alkaline phosphatase
Partially obstructing stones not impeding
the biliary outflow (false –) 
Spontaneous stone passage
to the duodenum (false +)  
Stone migration from the gallbladder
in the interval between blood
sampling and surgery (false –)  
Compression of the common
bile duct by an oedematous
pancreas in cases of
pancreatitis (false +)  
Sludge that passes undetected on 
intraoperative cholangiography (false +) 
Secretory hepatic dysfunction
caused by shock, general illness
or Gilbert’s syndrome (false +)  
Liver
Duodenum
Pancreas 
Gallbladder
Sphincter of Oddi dysfunction (false +)
Figure 2 Causes of false positive or false negative findings of elevated alkaline phosphatase (ALP) or bilirubin
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the pancreatitis itself, which generates oedema that compresses it,
rather than by the CBDS.25,26 Furthermore, the secretory process of
expelling conjugated bilirubin into the bile is highly energy-
dependent and sensitive to hepatic insult.27 Acute pancreatitis and
cholangitis may thus cause dysfunction of the hepatic secretory
process as a result of inflammatory reactions and diminished
blood flow secondary to shock.
Thus, when dealing patients with acute pancreatitis and
elevated liver function tests, it is worth noting that although CBDS
may be a cause of pancreatitis, the predictive values of ALP and
bilirubin levels are rather poor in this group of patients.
A history of acute biliary pancreatitis correlated poorly with the
presence of CBDS. The risk for CBDS was only 20% among
patients with a history of acute biliary pancreatitis.
This low correlation between CBDS and a recent history of
acute biliary pancreatitis was also observed in a previous study4
and is most probably explained by the likelihood that the stones
that induce acute pancreatitis are often too small to remain
trapped in the CBD. When they are expelled into the distal CBD
from the gallbladder, these stones may only temporarily obstruct
the flow of pancreatic juice into the duodenum, thereby giving rise
to acute pancreatitis, and then continue their journey to the
duodenum. Larger stones, however, seem to become trapped more
proximally in the CBD where they do not interfere with the exo-
crine function of the pancreas and thus never cause pancreatitis.
This theory is supported by findings of gallstones in the stools of
97% of patients with biliary pancreatitis.28
A history of acute cholecystitis was not significantly associated
with an increased risk for CBDS. In fact, only 8.7% of patients
with a history of ongoing or previous acute cholecystitis were
diagnosed with CBDS, compared with 12% of patients without a
history of cholecystitis. Common bile duct stones were thus more
common in patients without a history of acute cholecystitis. This
may be because the impacted stone that provokes the cholecystitis
may also have a protective effect on the CBD by preventing addi-
tional gallstones from entering the bile ducts from the gallbladder,
such as may occur during manipulation in surgery.
Common bile duct stones were found in 22% of patients at the
university clinic, 11% of patients at the municipal clinic and 5% of
patients at the short-stay clinic. Operating time, conversion rate
and the frequency of primary open operations were all consider-
ably higher at the university clinic than at the short-stay clinic,
which indicates that the preoperative planning succeeded in
directing the more complicated procedures to the university clinic
(Table 1).
A common problem in many previous studies refers to the
incomplete description of the patient sample. This may be a cause
of selection bias. Furthermore, a reference standard for diagnosing
CBDS, such as IOC, is not always described. A large meta-analysis
performed in 1996 and based on 2221 articles dealing with pre-
dictors of CBDS was able to include only 22 studies.29
This is the first prospective, population-based study dedicated
to this subject, and the only study to assess the predictive ability of
bilirubin and ALP levels sampled weeks before surgery, as is nec-
essary in order to facilitate the planning of the procedure. The
time from sampling of liver function tests to surgery varied from
a few days to 4 weeks. Thus, it is possible that patients with CBDS
passed their stones into the duodenum before surgery, or that
stones may have migrated into the CBD after the samples were
obtained. The migration of CBDS is probably a more dynamic
process than previously thought. In a study by Collins et al., in
which all patients with asymptomatic CBDS diagnosed by IOC
during cholecystectomy were managed conservatively and fol-
lowed with repeated postoperative cholangiography through a
transcystic catheter, up to 30% of the CBDS were observed to pass
spontaneously within 6 weeks of cholecystectomy.30 However, this
study protocol was not designed to analyse the predictive values of
ALP and bilirubin levels sampled at different time intervals before
surgery.
A weakness of the present study refers to the fixed cut-off
levels for ALP and bilirubin. Our original reason for using fixed
cut-off levels referred to the fact that obstructing processes in the
CBD should be suspected if only one of the predictors was
elevated. We also used total bilirubin and not conjugated biliru-
bin as a predictor, principally because, by tradition, conjugated
bilirubin is not a standard analysis in many Swedish hospitals
and has to be ordered separately. By differentiating between con-
jugated and unconjugated bilirubin, it is possible to distinguish
between elevated levels caused by a mechanical CBD obstruc-
tion, as in the case of CBDS, or by increased production of
haem, as seen in haemolysis, or defective conjugation capacity, as
in Gilbert’s syndrome. Both mechanisms, however, cause total
bilirubin to be elevated.
Conclusions
Although elevated ALP and bilirubin levels were the best predic-
tors of CBDS in the present study, the number of false positive and
false negative findings was relatively high and less than half of the
patients with elevated bilirubin or ALP were found to have CBDS
on IOC. The best agreement was seen in patients who underwent
elective surgery, which indicates that mechanisms other than
CBDS were responsible for elevating ALP and/or bilirubin in
patients with acute cholecystitis or a history of acute biliary pan-
creatitis. Normal bilirubin or ALP levels seen in patients with
CBDS verified at surgery may reflect the presence of partially
obstructive stones or the migration of stones from the gallbladder
to the CBD in the interval between blood sampling and surgery, or
even during surgery when the gallbladder is manipulated.
Elevated liver function values in the absence of CBDS may reflect
the migration of stones from the CBD to the duodenum, sludge,
CBD compression caused by pancreatitis, or hepatic dysfunction
caused by shock or Gilbert’s syndrome. Pancreatitis was not found
to be a significant predictor of CBDS. Common bile duct stones
were less common in patients with cholecystitis, indicating that an
impacted stone provoking cholecystitis may have a protective
526 HPB
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effect against CBDS by preventing additional stones from trans-
locating from the gallbladder into the CBD.
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